← TrialMatch
HomeTrials

Oromyofunctional Therapy: a Rehabilitation Program for OSA in Children With Down Syndrome

Obstructive sleep apnea (OSA) is a prevalent medical condition with important implications for overall health and quality of life in both children. Therefore, it is important to treat OSA early and effectively. Children with Down syndrome and Prader-Willi syndrome have many predisposing factors for OSA, including mouth

Condition(s)Obstructive Sleep Apnea (OSA), Orofacial Myofunctional Disorders
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryObstructive sleep apnea (OSA) is a prevalent medical condition with important implications for overall health and quality of life in both children. Therefore, it is important to treat OSA early and effectively. Children with Down syndrome and Prader-Willi syndrome have many predisposing factors for OSA, including mouth breathing, narrow upper airways resulting from craniofacial abnormalities, and generalized hypotonia, which increases UA collapsibility and multilevel obstructions. Adenotonsillectomy is the first-line treatment. Unfortunately, up to 55% of children with Down syndrome and up to 79% of children with Prader-Willi syndrome suffer from residual OSA after adenotonsillectomy. Therefore, exploring other treatment options for these children is an interesting and relevant avenue for
Who can participateInclusion Criteria: * Children aged between 4-18 * Diagnosed with Down syndrome or Prader-Willi syndrome * Diagnosed with Obstructive Sleep Apnea on Polysomnography (AHI\<1) Exclusion criteria: * History of Orofacial Myofunctional Therapy * Undergoing an orthodontic procedure during the study period * Undegoing an OSA treatment during the study period * Orofacial congenital deformities (not related to Down syndrome or Prader-Willi syndrome)
Ages4 Years to 18 Years
SexAll
Lead sponsorUniversity Ghent
LocationsGhent, Belgium
Start date2024-04-15
NCT IDNCT07122505
Official listinghttps://clinicaltrials.gov/study/NCT07122505

🔍 Search all trials →